Germany Analysis

Pages

Industry Trend Analysis - Germany To Become Increasingly Important For Stada - SEPT 2016

Stada Arzneimittel's Central and Eastern Europe sales region saw sales in this latest quarter plummet, hampered by the ongoing economic situation in Russia and Serbia. Of more comfort to Stada has been performance in Germany, which is showing evidence of countering the country's long-standing financial squeeze on generics. The domestic market is set to become increasingly important as a bulwark...

READ FULL ARTICLE

Industry Trend Analysis - Increased Outsourcing Requirements Changing CRO Role - JULY 2016

The evolving big pharma model is catalysing deep shifts within the CRO industry, with a move towards closer collaborative relationships. Whilst CROs initially attempted to draw in big pharma partnerships though size advantages, innovation is now becoming increasingly key. CROs that offer drug discovery solutions based on data-driven platforms will be of particular interest.

READ FULL ARTICLE

Industry Trend Analysis - Generic Drug Prices Will Continue To Fall - JUNE 2016

Downward pressure on the prices of generic medicines in Germany as a result of tenders raising the level of competition, and the ultimate commoditisation of off-patent medicines, draws attention to the inherent challenges for generic drugmakers looking to profit from the government's focus on cost-containment within the healthcare sector. While the loss of value in the patented drugs segment...

READ FULL ARTICLE

Industry Trend Analysis - Focus On Life Sciences Business Will Support Future Growth - MAY 2016

Bayer's strategical direction towards a pure life sciences company will increase its appeal to investors in 2016. De-diversification represents a growing trend within the pharmaceutical industry as companies look to focus their attention on core growth drivers. Bayer's crop science division will come under increasing pressure over the coming years as the merger between Dow Chemical and DuPont...

READ FULL ARTICLE

Industry Trend Analysis - Collaboration Key To Arena And BI's Neuroscience Research - APR 2016

Boehringer Ingelheim and Arena's collaboration is indicative of the high demand for novel neurological drugs due to an increasing burden of disease. The deal will go a long way to support Arena's development of new compounds after its debut product, Belviq, disappointed. It also marks a shift towards a more open research model from Boehringer Ingelheim, as it attempts to overcome a loss of...

READ FULL ARTICLE

Pages